reports
Krystal Biotech to Present at Upcoming Scientific Conferences
Krystal Biotech to Present at Upcoming Scientific Conferences PITTSBURGH, April 24, 2025 (GLOBE NEWSWIRE) -- (the “Company”) (NASDAQ: KRYS) announced today that the Company will be presenting on multiple programs in the lung, eye, and skin at upcoming scientific conferences being held in May and June. Presentation details are outlined below. American Society of Gene & Cell Therapy (ASGCT) 28th Annual MeetingInvited Oral Presentation Title: HSV-1 as a vector system for targeting respiratory tissues in genetic pulmonary diseasePresenter: Trevor Parry, PhDDate and Time: May 17, 202...
Krystal Biotech to Report First Quarter 2025 Financial Results on May ...
Krystal Biotech to Report First Quarter 2025 Financial Results on May 6, 2025 PITTSBURGH, April 17, 2025 (GLOBE NEWSWIRE) -- (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that it will report its first quarter 2025 financial results on Tuesday, May 6, 2025, prior to the open of U.S. markets. The Company’s management will also host a conference call and webcast at 8:30 am ET on Tuesday, May 6, 2025, to discuss the financial results and provide a business update. Investors and the general public can access the live webcast at: . For those unabl...
Jeune Aesthetics Appoints Marc Forth as Chief Executive Officer
Jeune Aesthetics Appoints Marc Forth as Chief Executive Officer PITTSBURGH, April 07, 2025 (GLOBE NEWSWIRE) -- (“Jeune”), a wholly owned subsidiary of (“Krystal”) (NASDAQ: KRYS) leveraging Krystal’s clinically validated gene-delivery platform to fundamentally address and reverse the biology of aging skin, announced today the appointment of Marc Forth as Chief Executive Officer (CEO), effective today. A veteran of the healthcare industry, Mr. Forth has over 30 years of commercial and executive leadership experience, with an extensive track record of building innovative companies as well ...
Krystal Biotech Inc: 2 directors
Two Directors at Krystal Biotech Inc sold/sold after exercising options 50,000 shares at 177.791USD. The significance rating of the trade was 75/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's direct...
Krystal Biotech Receives Positive CHMP Opinion for VYJUVEK® for the Tr...
Krystal Biotech Receives Positive CHMP Opinion for VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa EC approval decision anticipated in second quarter of 2025 PITTSBURGH, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today welcomed the European Medicines Agency's (EMA’s) that its Committee for Medicinal Products for Human Use (CHMP) has issued a positive recommendation for the European Commission (EC) to approve VYJUVEK® (beremagene geperpavec-svdt, or B-VEC) for the treatment of wounds in...
Krystal Biotech to Present at TD Cowen 45th Annual Health Care Confere...
Krystal Biotech to Present at TD Cowen 45th Annual Health Care Conference PITTSBURGH, Feb. 26, 2025 (GLOBE NEWSWIRE) -- . (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that the Company will participate in the TD Cowen 45th Annual Health Care Conference on March 4, 2025, in Boston. Krish S. Krishnan, Chairman and Chief Executive Officer, will take part in a fireside chat scheduled at 1:50 pm ET and host investor meetings throughout the day. A webcast of the presentation will be available beginning at 1:50 pm ET on Tuesday, March 4, 2025 and wil...
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
SHAK SHAKE SHACK INC. CLASS A
SKT TANGER FACTORY OUTLET CENTERS INC.
RGR STURM RUGER & COMPANY INC.
POWI POWER INTEGRATIONS INC.
MD MEDNAX INC.
ICLR ICON PLC
HAS HASBRO INC.
CRAI CHARLES RIVER ASSOCIATES INC.
BMRN BIOMARIN PHARMACEUTICAL INC.
AVNW AVIAT NETWORKS
LKO LAKES OIL N.L.
MX MAGNACHIP SEMICONDUCTOR CORP.
BELFB BEL FUSE INC. CL B
LAUR LAUREATE EDUCATION INC. CLASS A
PMTS CPI CARD GROUP
KRYS KRYSTAL BIOTECH INC
SWTX SPRINGWORKS THERAPEUTICS
CSTM CONSTELLIUM SE CLASS A
AM ANTERO MIDSTREAM CORP.
CADL CANDEL THERAPEUTICS INC
FTAI FORTRESS TRANSN & INFRAS INVS LLC
Krystal Biotech Announces Fourth Quarter and Full Year 2024 Financial ...
Krystal Biotech Announces Fourth Quarter and Full Year 2024 Financial and Operating Results Fourth quarter revenues increased 116% to $91.1 million versus fourth quarter of 2023 Full year revenues increased 473% to $290.5 million versus 2023 CFF TDN granted full sanctioning of KB407 Phase 1 protocol Strong balance sheet, ending the quarter with $749.6 million in cash and investments PITTSBURGH, Feb. 19, 2025 (GLOBE NEWSWIRE) -- (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today reported financial results for the fourth quarter and full year ending Decem...
Krystal Biotech to Report Fourth Quarter and Full Year 2024 Financial ...
Krystal Biotech to Report Fourth Quarter and Full Year 2024 Financial Results on February 19, 2025 PITTSBURGH, Feb. 06, 2025 (GLOBE NEWSWIRE) -- (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that it will report its fourth quarter and full year 2024 financial results on Wednesday, February 19, 2025, prior to the open of U.S. markets. The Company’s management will also host a conference call and webcast at 8:30 am ET on Wednesday, February 19, 2025, to discuss the financial results and provide a business update. Investors and the general public...
Jeune Aesthetics Appoints Nishant Saxena as Chief Financial Officer
Jeune Aesthetics Appoints Nishant Saxena as Chief Financial Officer PITTSBURGH, Jan. 14, 2025 (GLOBE NEWSWIRE) -- (“Jeune”), a wholly owned subsidiary of (“Krystal”) (NASDAQ: KRYS) leveraging Krystal’s clinically validated gene-delivery platform to fundamentally address and reverse the biology of aging skin, announced today the appointment of Nishant Saxena as Chief Financial Officer (CFO), effective January 15, 2025. Mr. Saxena has over 20 years of experience in finance, strategy, capital markets, mergers and acquisitions, and corporate development. Most recently, he was a Managing Dir...
Krystal Biotech Announces Early Evidence of Monotherapy Activity in He...
Krystal Biotech Announces Early Evidence of Monotherapy Activity in Heavily Pre-Treated Patients with Advanced Non-Small Cell Lung Cancer Preliminary clinical data in post-anti-PD-1 NSCLC patients demonstrated a 27% ORR and 73% DCR in monotherapy trial Monotherapy activity with inhaled KB707 provides further evidence of successful repeat administration of HSV-1 based inhaled lung gene delivery and builds on recent clinical data update for CF and AAT deficiency respiratory disease programs PITTSBURGH, Dec. 18, 2024 (GLOBE NEWSWIRE) -- (the “Company”) (NASDAQ: KRYS), a commercia...
Krystal Biotech Announces Initial Clinical Update for Rare Respiratory...
Krystal Biotech Announces Initial Clinical Update for Rare Respiratory Disease Programs KB408 and KB407 Including Early Clinical Evidence of Gene Delivery to the Lung of AATD Patients and Increase in Lung AAT to Therapeutic Levels Clear evidence of SERPINA1 gene delivery and AAT expression following KB408 administration in AATD patients Both KB408 for AATD patients and KB407 for patients with cystic fibrosis were safe and well tolerated at all dosing regimens evaluated to date Conditional sanctioning of the KB407 Phase 1 CF Study CORAL-1 protocol by CFF TDN Investor call and webcast to b...
Krystal Biotech Provides Update on EMA’s Ongoing Regulatory Review of ...
Krystal Biotech Provides Update on EMA’s Ongoing Regulatory Review of B-VEC for Dystrophic Epidermolysis Bullosa CHMP opinion now expected in 1Q 2025 No Major Objections outstanding; continue to expect Germany launch in 2Q 2025 PITTSBURGH, Dec. 09, 2024 (GLOBE NEWSWIRE) -- . (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) cancelled the Oral Explanation regarding the Company’s Marketing Authorization Application for beremagene geperpavec-svdt (B-VEC...
Krystal Biotech to Present at Upcoming Investor Conferences
Krystal Biotech to Present at Upcoming Investor Conferences PITTSBURGH, Nov. 27, 2024 (GLOBE NEWSWIRE) -- . (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that Krish S. Krishnan, Chairman and Chief Executive Officer, will take part in fireside chats and host investor meetings at two upcoming investor conferences: Citi’s 2024 Global Healthcare Conference on December 3, 2024 in Miami, Florida; fireside chat scheduled for 8:45 am ET7th Annual Evercore HealthCONx Conference on December 4, 2024 in Coral Gables, Florida; fireside chat scheduled for 2:...
Krystal Biotech to Present at Stifel 2024 Healthcare Conference
Krystal Biotech to Present at Stifel 2024 Healthcare Conference PITTSBURGH, Nov. 12, 2024 (GLOBE NEWSWIRE) -- . (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that the Company will participate in the Stifel 2024 Healthcare Conference on November 18, 2024, in New York. Krish S. Krishnan, Chairman and Chief Executive Officer, will take part in a fireside chat scheduled at 10:55 am ET and host investor meetings throughout the day. A webcast of the presentation will be available beginning at 10:55 am ET on Monday, November 18, 2024 and will be post...
Krystal Biotech to Present at Guggenheim Securities Healthcare Innovat...
Krystal Biotech to Present at Guggenheim Securities Healthcare Innovation Conference PITTSBURGH, Nov. 06, 2024 (GLOBE NEWSWIRE) -- . (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that the Company will participate in the Guggenheim Securities Healthcare Innovation Conference on November 12, 2024, in Boston. Krish S. Krishnan, Chairman and Chief Executive Officer, will take part in a fireside chat scheduled at 1:30 pm ET and host investor meetings throughout the day. A webcast of the presentation will be available beginning at 1:30 pm ET on Tues...
Krystal Biotech Announces Third Quarter 2024 Financial Results and Pro...
Krystal Biotech Announces Third Quarter 2024 Financial Results and Provides Business Updates Net product revenue of $83.8 million in 3Q and $250.1 million since launch in August 2023 JNDA for B-VEC filed and on track for commercial launches in Japan and Europe in 2025 French health authority approved pre-marketing early reimbursed access for B-VEC in France under the Accès Précoce (AP1) program; AP1 program for DEB patients access expected to start in 4Q 2024 Advancing Jeune Aesthetics’ KB301 to Phase 2 after positive results in Phase 1 Clinical updates on AATD and onco...
Krystal Biotech to Report Third Quarter 2024 Financial Results on Nove...
Krystal Biotech to Report Third Quarter 2024 Financial Results on November 4, 2024 PITTSBURGH, Oct. 28, 2024 (GLOBE NEWSWIRE) -- (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that it will report its third quarter 2024 financial results on Monday, November 4, 2024, prior to the open of U.S. markets. The Company’s management will also host a conference call and webcast at 8:30 am ET on Monday, November 4, 2024, to discuss the financial results and provide a business update. Investors and the general public can access the live webcast at: . For...
Krystal Biotech to Present at 2024 Cantor Global Healthcare Conference
Krystal Biotech to Present at 2024 Cantor Global Healthcare Conference PITTSBURGH, Sept. 13, 2024 (GLOBE NEWSWIRE) -- . (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that the Company will participate in the 2024 Cantor Global Healthcare Conference on September 18, 2024, in New York. Krish S. Krishnan, Chairman and Chief Executive Officer, will take part in a fireside chat scheduled at 1:20 pm ET and host investor meetings throughout the day. A webcast of the presentation will be available beginning at 1:20 pm ET on Wednesday, September 18,...
Krystal Biotech to Present at H.C. Wainwright 26th Annual Global Inves...
Krystal Biotech to Present at H.C. Wainwright 26th Annual Global Investment Conference PITTSBURGH, Sept. 06, 2024 (GLOBE NEWSWIRE) -- . (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that the Company will participate in the H.C. Wainwright 26th Annual Global Investment Conference on September 10, 2024, in New York. Krish S. Krishnan, Chairman and Chief Executive Officer, is scheduled to give a company presentation at 12:30 pm ET and host investor meetings throughout the day. A webcast of the presentation will be available beginning at 12:30 pm ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.